Brought to you by 
Galapagos raises €53.9mm through private placement
26 Apr 2013
Executive Summary
Galapagos NV raised €53.9mm ($70.1mm) through the sale of 2.7mm new shares at €20 (a 5% premium) to US and European institutional investors. The company is developing small molecules and antibodies for inflammation, metabolic diseases, cystic fibrosis, rheumatoid arthritis, and other serious conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galapagos raises €53.9mm through private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice